-$0.80 Earnings Per Share Expected for NewLink Genetics Corporation (NLNK) This Quarter
Brokerages expect NewLink Genetics Corporation (NASDAQ:NLNK) to announce earnings per share (EPS) of ($0.80) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for NewLink Genetics Corporation’s earnings, with estimates ranging from ($0.87) to ($0.75). NewLink Genetics Corporation posted earnings of ($0.54) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 48.1%. The firm is expected to report its next quarterly earnings report on Tuesday, November 7th.
On average, analysts expect that NewLink Genetics Corporation will report full year earnings of ($2.79) per share for the current financial year, with EPS estimates ranging from ($3.05) to ($2.64). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.48) per share, with EPS estimates ranging from ($3.29) to ($1.71). Zacks’ earnings per share averages are an average based on a survey of research firms that follow NewLink Genetics Corporation.
NewLink Genetics Corporation (NASDAQ:NLNK) last released its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.21. The business had revenue of $10.37 million for the quarter, compared to the consensus estimate of $2.65 million. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%.
A number of research firms recently issued reports on NLNK. ValuEngine cut NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday. Stifel Nicolaus increased their price objective on NewLink Genetics Corporation from $14.00 to $29.00 and gave the company a “buy” rating in a report on Monday. Cantor Fitzgerald reissued a “buy” rating and issued a $26.00 price objective on shares of NewLink Genetics Corporation in a report on Friday, September 8th. Robert W. Baird raised NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $8.00 to $22.00 in a report on Friday, September 8th. Finally, Jefferies Group LLC raised NewLink Genetics Corporation from a “hold” rating to a “buy” rating and increased their price objective for the company from $7.00 to $26.00 in a report on Friday, September 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. NewLink Genetics Corporation currently has an average rating of “Buy” and a consensus price target of $24.17.
NewLink Genetics Corporation (NASDAQ:NLNK) traded down 3.56% during mid-day trading on Friday, hitting $12.72. 3,282,243 shares of the company traded hands. The company’s market capitalization is $374.24 million. NewLink Genetics Corporation has a one year low of $5.90 and a one year high of $25.17. The company’s 50-day moving average price is $8.35 and its 200 day moving average price is $12.85.
COPYRIGHT VIOLATION NOTICE: “-$0.80 Earnings Per Share Expected for NewLink Genetics Corporation (NLNK) This Quarter” was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/15/0-80-earnings-per-share-expected-for-newlink-genetics-corporation-nlnk-this-quarter-2.html.
Hedge funds have recently made changes to their positions in the company. Brandes Investment Partners LP acquired a new stake in shares of NewLink Genetics Corporation during the first quarter valued at about $221,000. UBS Asset Management Americas Inc. acquired a new stake in shares of NewLink Genetics Corporation during the first quarter valued at about $297,000. Gotham Asset Management LLC acquired a new stake in shares of NewLink Genetics Corporation during the first quarter valued at about $313,000. American International Group Inc. boosted its stake in shares of NewLink Genetics Corporation by 7.1% during the first quarter. American International Group Inc. now owns 13,321 shares of the biotechnology company’s stock valued at $321,000 after purchasing an additional 880 shares in the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in shares of NewLink Genetics Corporation during the second quarter valued at about $125,000. 54.78% of the stock is currently owned by hedge funds and other institutional investors.
NewLink Genetics Corporation Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.